文献速递心血管US

TAVR与SAVR的长期瓣膜性能:PARTNER I试验报告

Long-Term Valve Performance of TAVR and SAVR: A Report From the PARTNER I Trial.
PubMed 文献 · JACC Cardiovasc Imaging · 2016-12-08

本研究对PARTNER I试验中86例TAVR和48例SAVR患者配对比较了术后首次与5年超声心动图。TAVR组主动脉瓣面积和平均跨瓣压差在5年时保持稳定,主动脉瓣及左室流出道峰值流速和支架内流速下降,左室质量指数显著消退,总AR、经瓣AR和瓣周AR均无变化;SAVR组呈现相似趋势。结论认为存活至5年的患者中SAPIEN TAVR与SAVR的瓣膜性能和心脏血流动力学在植入后保持稳定。

要点

  • TAVR术后5年主动脉瓣面积和平均跨瓣压差保持稳定,平均压差由11.5±5.4 mmHg变为11.0±6.3 mmHg(P=0.41)。
  • TAVR术后5年主动脉瓣峰值流速、左室流出道峰值流速和支架内流速均下降(P分别为0.03、0.008和0.015)。
  • TAVR术后5年总AR、经瓣AR和瓣周AR均无变化(P分别为0.40、0.37和0.26),左室质量指数显著消退(P<0.0001)。

核心结论

  • 纵向评估显示,存活至5年的患者中SAPIEN TAVR与SAVR植入后瓣膜性能和心脏血流动力学保持稳定。

研究设计与样本

  • PARTNER I试验(NCT00530894)的纵向超声心动图分析,纳入TAVR 86例和SAVR 48例有术后首次和5年配对超声心动图的患者,采用配对t检验或McNemar分析比较。

关键影像表现/征象

  • TAVR术后5年主动脉瓣面积无显著变化(P=0.35)。
  • TAVR术后5年主动脉瓣峰值流速和左室流出道峰值流速下降(P分别为0.03和0.008),支架内流速亦下降(P=0.015)。
  • TAVR术后5年总AR、经瓣AR和瓣周AR均无变化(P分别为0.40、0.37和0.26)。
  • TAVR术后5年左室质量指数显著消退(P<0.0001),每搏输出量指数和心指数保持稳定(P分别为0.16和0.25)。
  • SAVR患者的纵向评估呈现相似趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of this study was to evaluate the long-term performance of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) through longitudinal echocardiographic analysis.

BACKGROUND: The long-term performance of the SAPIEN TAVR is not well-described. Therefore, we examined the hemodynamic and valvular profile of the SAPIEN TAVR over 5 years.

METHODS: All patients receiving TAVR or SAVR with first post-implant (FPI) and 5-year echoes were analyzed for aortic valve (AV) peak velocity, AV mean gradient, AV area, peak left ventricular (LV) outflow tract and in-stent velocities, Doppler velocity index, aortic regurgitation (AR), LV mass index, stroke volume index, and cardiac index. The FPI and 5-year data were compared using a paired t test or McNemar's analyses.

RESULTS: There were 86 TAVR and 48 SAVR patients with paired FPI and 5-year echocardiograms. Baseline characteristics were similar between groups. The AV area did not change significantly 5 years after TAVR (p = 0.35). The AV mean gradient also remained stable: 11.5 ± 5.4 mm Hg at FPI to 11.0 ± 6.3 mm Hg at 5 years (p = 0.41). In contrast, the peak AV and LV outflow tract velocities decreased (p = 0.03 and p = 0.008, respectively), as did in-stent velocity (p = 0.015). Correspondingly, the TAVR Doppler velocity index was unchanged (p = 0.07). Among TAVR patients, there was no change in total AR (p = 0.40), transvalvular AR (p = 0.37), or paravalvular AR (p = 0.26). Stroke volume index and cardiac index remained stable (p = 0.16 and p = 0.25, respectively). However, there was a significant regression of LV mass index (p < 0.0001). The longitudinal evaluation among SAVR patients revealed similar trends. There was a low rate of adverse events among TAVR and SAVR patients alive at 5 years.

CONCLUSIONS: Longitudinal assessment of the PARTNER I trial (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial) demonstrates that valve performance and cardiac hemodynamics are stable after implantation in both SAPIEN TAVR and SAVR in patients alive at 5 years. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Daubert MA, Weissman NJ, Hahn RT, et al. Long-Term Valve Performance of TAVR and SAVR: A Report From the PARTNER I Trial. JACC Cardiovasc Imaging. 2016. PMID: 28017714. doi:10.1016/j.jcmg.2016.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。